Author Information
Dr. Eric Keith Rowinsky is a prominent researcher affiliated with Vivolux AB, located at Uppsala Science Park, c/o NEXTTOBE AB, Dag Hammarskjölds väg 40c, SE-751 83, Uppsala, Sweden. His research primarily focuses on advanced solid malignancies and immunotherapy, contributing significantly to the field of oncology.Research Contributions
Dr. Rowinsky has made substantial contributions to the field of oncology, particularly in the development of novel therapeutic strategies for treating advanced solid tumors. His recent studies include the development and clinical evaluation of various immunotherapies and targeted treatments such as HMBD-002, an anti-VISTA antibody, and RGX-104, a liver-X receptor agonist. These studies aim to improve the efficacy and safety of cancer treatments, offering new hope for patients with refractory malignancies.Aliases
Eric Keith Rowinsky is known by several aliases in academic publications, including E. K. Rowinsky, Eric K. Rowinsky, E Rowinsky, Eric Rowinsky, Eric K Rowinsky, E.k. Rowinsky, Erick K Rowinsky, E. Rowinsky, and E K Rowinsky.Publication and Citation Metrics
| Metric |
Value |
| Total Citation Count |
44,529 |
| h-index |
88 |
| Total Paper Count |
487 |
